Kitov Pharmaceuticals names Gil Ben-Menachem VP of business development

8 January 2016

Israel-based Kitov Pharmaceuticals (TASE: KTOV) has appointed Gil Ben-Menachem as vice president business development.

The appointment follows Kitov's recent announcement that the pivotal Phase III trial of its lead drug candidate KIT-302 successfully met its primary endpoint. A combination drug, KIT-302, simultaneously treats osteoarthritis pain as well as hypertension, which is a common side effect of non-steroidal anti-inflammatory (NSAID) drugs.

Kitov chief executive Isaac Israel said: "Dr Ben-Menachem has a very strong track record of performance in the industry and we believe his appointment will drive Kitov's business development efforts towards achieving our strategic goals."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK